Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Alkermes, Merck Enter Clinical Trial and Supply Agreement | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Alkermes, Merck Enter Clinical Trial and Supply Agreement

To evaluate nemvaleukin alfa in combination with Keytruda in patients with platinum-resistant ovarian cancer.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alkermes has entered into a clinical trial collaboration and supply agreement with MSD, a tradename of Merck, for a planned phase 3 study to evaluate nemvaleukin alfa, Alkermes’ novel investigational engineered interleukin-2 (IL-2) variant immunotherapy, in combination with MSD’s Keytruda (pembrolizumab), in comparison to investigator choice chemotherapy in patients with platinum-resistant ovarian cancer.
 
Alkermes is responsible for conducting the phase 3 study, which is planned to initiate in the second half of 2021.
 
“We are pleased to collaborate with MSD to evaluate nemvaleukin in combination with Keytruda in patients with platinum-resistant ovarian cancer, a patient population for which there are limited treatment options available and overall survival remains low. Importantly, there are no anti-PD-1 treatments currently approved for this tumor type,” said Jessicca Rege, vice president, head of oncology, Alkermes.
 
Nemvaleukin in combination with Keytruda has demonstrated antitumor activity in heavily pre-treated patients with platinum-resistant ovarian cancer in the ongoing ARTISTRY-1 study.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics